References:

1. Graudal NA, et al. Radiographic progression in rheumatoid arthritis. Arthritis Rheum. 1998;41(8):1470-1480.

2. van der Pouw Kraan TC, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 2003;48:2132-2145.

3. Sokka T, et al. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol. 2009;36(7):1387-1390.

4. Grigor C, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA Study): a single-blind randomised controlled trial. Lancet. 2004;364:263-269.

5. Rantalaiho V, et al, for the FIN-RACo Trial Group. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12(3):R122.

6. Verstappen SMM, et al, on behalf of the Utrecht Rheumatoid Arthritis Cohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-1449.

7. Goekoop-Ruiterman YPM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-3390.

8. Saag KG, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.

9. Combe B, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.

10. Smolen JS, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.

11. Shen Y, Dirven L. Cavet G, et al. Serum biomarker combinations to assess disease activity in the BeSt study. Presented at: EULAR 2010 Annual European Congress of Rheumatology; June 16-19, 2010: Rome, Italy. Supported by Crescendo Bioscience, Inc.

12. van Dinther-Janssen AC, Horst E, Koopman G, et al. The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol. 1991;147(12):4207-4210.

13. Tokuhira M, Hosaka S, Volin MV, et al. Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum. 2000;43(5):1122-1133.

14. Seemayer CA, Kuchen S, Kuenzler P, et al. Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis. Am J Pathol. 2003;162(5):1549-1557.

15. Koch AE, Burrows JC, Haines GK, Carlos TM, Harlan JM, Leibovich SJ. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest. 1991;64(3):313-320.

16. Xu JW, Ma J, Li TF, et al. Expression of epidermal growth factor and transforming growth factor alpha in interfacial membranes retrieved at revision total hip arthroplasty. Ann Rheum Dis. 2000;59(10):822-827.

17. Hiraoka K, Sasaguri Y, Komiya S, Inoue A, Morimatsu M. Cell proliferation-related production of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin) by cultured human rheumatoid synovial fibroblasts. Biochem Int. 1992;27(6):1083-1091.

18. Huh YH, Kim SH, Kim SJ, Chun JS. Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J Biol Chem. 2003;278(11):9691-9697.

19. Wang Y, Ripperger J, Fey GH, et al. Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells. Hepatology. 1999;30(3):682-697.

20. Afuwape AO, Kiriakidis S, Paleolog EM. The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis. Histol Histopathol. 2002;17(3):961-972.

21. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol. 1994;152(8):4149-4156.

22. Niida S, Kaku M, Amano H, et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med. 1999;190(2):293-298.

23. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16(3-4):249-284.

24. Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8(suppl 2):S5.

25. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology. 2010;49(1):15-24.

26. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296(5573):1634-1635.

27. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;10:578-582.

28. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-543.

29. Flannery CR, Lark MW, Sandy JD. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan: evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem. 1992;267:1008-1014.

30. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry. 1990;29:10261-10270.

31. Okada Y, Takeuchi N, Tomita K, Nakanishi I, Nagase H. Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis. 1989;48(8):645-653.

32. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803-25810.

33. Kirkpatrick RB, Emery JG, Connor JR, Dodds R, Lysko PG, Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res. 1997;237(1):46-54.

34. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285:926-931.

35. Ling H, Recklies AD.The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J. 2004;380(pt 3):651-659.

36. Kotzin BL, Falta MT, Crawford F, et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci USA. 2000;97(1):291-296.

37. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-432.

38. Reseland JE, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res. 2001;16(8):1426-1433.

39. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543-546.

40. Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002;17(2):200-209.

41. Yadav VK, Oury F, Suda N, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138(5):976-989.

42. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307-312.

43. Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem. 2006;99(3):824-834.

44. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789-5795.

45. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331(2):520-526.

46. Benigni F, Fantuzzi G, Sacco S, et al. Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood. 1996;87(5):1851-1854.

47. Zhang N, Ahsan MH, Purchio AF, West DB. Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition. J Immunol. 2005;174(12):8125-8134.

48. Kisilevsky R, Tam SP. Acute phase serum amyloid A, cholesterol metabolism, and cardiovascular disease. Ped Pathol Mol Med. 2002;21(3):291-305.

49. Kumon Y, Suehiro T, Hashimoto K, Nakatani K, Sipe JD. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J Rheumatol. 1999;26:785.

50. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res. 2000;2:142.

51. Weinhold B, Ruther U. Interleukin-6-dependent and independent regulation of the human C-reactive protein gene. Biochem J. 1997;327:425-429.

52. Zhang D, Jiang SL, Rzewnicki D, Samols D, Kusher I. C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J. 1995;310:143-148.

53. Macintyre SS, Schultz D, Kushner I. Biosynthesis of C-reactive protein. Ann NY Acad Sci. 1982;389:76-87.

54. van der Meer IM, Oel HH, Hofman A, Pols HA, de Jong FH, Witteman JC. Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. The Rotterdam Coronary Calcification Study. Atherosclerosis. 2006;189(2):464-469.

55. Knowlton N, et al. Rheumatoid factor interferes with multiplex immunoassays in rheumatoid arthritis patients. Presented at: EULAR 2010 Annual European Congress of Rheumatology; June 16-19, 2010; Rome, Italy.

56. Eastman S, et al. Assay development for precise measurement of disease activity serum biomarkers. Presented at: EULAR 2010 Annual European Congress of Rheumatology; June 16-19, 2010; Rome, Italy.

57. Fleischmann R, et al, on behalf of the InFoRM Study Group. RA population characteristics in InFoRM: a longitudinal observational study. Presented at: EULAR 2010 Annual European Congress of Rheumatology; June 16-19, 2010; Rome, Italy.

58. Ramanujan S, et al. Multi-protein biomarker panel integrates critical pathophysiologic mechanisms in measurement of RA disease activity. Presented at: EULAR 2010 Annual European Congress of Rheumatology; June 16-19, 2010; Rome, Italy.

59. Bakker MF, et al. Performance of serum biomarkers and a pre-specified multivariate biomarker-based test to measure disease activity in early rheumatoid arthritis treated according to the CAMERA protocol. Presented at: EULAR 2010 Annual European Congress of Rheumatology; June 16-19, 2010; Rome, Italy.

60. Curtis JR, et al. Validation of a Multi-Biomarker Test for Rheumatoid Arthritis (RA) Disease Activity (Vectra(TM) DA) in a Multi-Cohort Study. Presentation 1782. ACR/ARHP 2010 Annual Scientific Meeting; November 6-11, 2010. Atlanta, GA, USA.

61. Inoue E, et al. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407-409.

62. Cavet G, Centola M, Shen Y, et al. Development of a multi-biomarker test for rheumatoid arthritis (RA). Ann Rheum Dis. 2010; 69(suppl 3):148.

References:

1. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-269.

2. Rantalaiho V, Korpela M, Laasonen L, et al, for the FIN-RACo Trial Group. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12(3):R122.

3. Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-1449.

4. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-3390.

5. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.

6. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.

7. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.

8. Barton JL, Imboden J, Graf J, et al. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res. 2010;62:857-864.

9. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%–45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol. 2009;36:1387-1390.

10. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58:2958-2967.

11. Garnero P, Geusens P, Landewé R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol. 2003:21(suppl 31):S54-S58.

12. Shen Y, Cavet G, Dirven L, et al. Discovery of serum biomarker combinations to assess disease activity in the BeSt study. Ann Rheum Dis. 2010;69(suppl 3):674.

13. Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. 2012; doi:10.1002/acr.21767 [Epub ahead of print].

14. Inoue E, Yamanaka H, Hara M, et al. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407-409.

15. Data on file, Crescendo Bioscience.

16. Hirata S, Dirven L, Cavet G, et al. A Novel Multi-Biomarker Disease Activity Score (Vectra DA algorithm score) Reflects Clinical Disease Activity Score and Health Assessment Questionnaire for Rheumatoid Arthritis in the BeSt Study. Poster 351. ACR 2011 Annual Scientific Meeting. Chicago, IL.

17. Weinblatt ME, Shadick NA, Manning W, et al. Use of a multi-biomarker score for rheumatoid arthritis disease activity (VectraTM DA) to assess response to therapy. Ann Rheum Dis. 2011;70(suppl 3):290.

18. Shadick NA, Chernoff D, Hamburger M, et al. Robustness of a novel multi-biomarker score for RA disease activity (VectraTM DA) across a spectrum of co-morbidities and smoking status. Ann Rheum Dis. 2011;70(suppl 3):446.

19. van der Helm-van Mil AHM, Knevel R, Qureshi F, et al. Evaluation of definitions of rheumatoid arthritis remission by assessing radiographic progression in the Leiden early arthritis cohort. Ann Rheum Dis. 2012;71(suppl 3):497.

20. Ma MH, Ramanujan S, Haney DJ et al. Biomarker signatures in rheumatoid arthritis patients with low disease activity: the REMIRA study. Ann Rheum Dis. 2011;70(suppl 3):537.

21. Allaart CF, Dirven L, Hirata S, et al. A multi-biomarker disease activity score predicts radiographic progression in the BeSt Study. Arthritis Rheum. 2011;63(suppl 10):S630.

22. Fleischmann R, Curtis J, Hamburger M, et al, on behalf of the InFoRM Study Group. RA population characteristics in InFoRM: a longitudinal observational study. Ann Rheum Dis. 2010;69(suppl 3):657.

23. Iannaccone CK, Lee YC, Cui J, et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study. Rheumatology. 2011;50:40-46.

24. Bakker MF, Cavet G, Jacobs JWG, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012; doi:10.1136/annrheumdis-2011-200963 [Epub ahead of print].

25. van der Linden MPM, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62:3537-3546.

26. van Aken J, van Bilsen JHM, Allaart CF. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol. 2003;21(suppl 31):S100-S105.

27. Hirata S, Haney DJ, Cavet G, et al. A multibiomarker disease activity score (VectraTM DA algorithm score) reflects clinical disease activity and tracks response in rheumatoid arthritis patients treated with anti-TNF therapy. Ann Rheum Dis. 2012;71(suppl 3):371.

28. Eastman S, Manning W, Qureshi F, et al. Characterization of a multiplex,12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012; doi:10.1016/j.jpba.2012.06.003 [Epub ahead of print].

Tools and Resources

Publications

Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, Tanaka Y, Huizinga TWJ, Allaart CF. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 2013, doi: 10.1093/rheumatology/kes362.

van der Helm-van Mil AHM, Knevel R, Cavet G, Huizinga TWJ, and Haney DJ. An Evaluation of Molecular and Clinical Remission in Rheumatoid Arthritis by Assessing Radiographic Progression. Rheumatology (Oxford). 2013. doi:10.1093/rheumatology/kes378.

Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care & Research. 2012; 64 (12):1794–1803.

Li W, Sasso E, Emerling D, Cavet G, Ford K. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Current Medical Research & Opinion. 2013; 29(1): 85-92.

Bakker MF, Cavet G, Jacobs JWG, Bijlsma JWJ, Haney D, Shen Y, Hesterberg L, Smith D, Centola M, van Roon JAG, Lafeber FPJG, Welsing PMJ. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis. 2012; doi:10.1136/annrheumdis-2011-200963

Burmester G, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, et al. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2012; doi:10.1136/annrheumdis-2012-202450.

Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan K, Turner M, Sutton C, Smith D, Haney D, Chernoff D, Hesterberg L, Carulli J, Taylor P, Shadick N, Weinblatt M, Curtis J. Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. PLOS ONE 2013 Apr 9;8(4):e60635. doi:10.1371/journal.pone.0060635.

Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, Hesterberg LK. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. Journal of Pharmaceutical and Biomedical Analysis, epub, June 5, 2012.

Zhao X, Qureshi F, Eastman PS, Manning W, Alexander C, Robinson W, Hesterberg L. Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. Journal of Immunological Methods. 2012; 378: 72-80

Presentations

Additional Crescendo Bioscience research and publications can be found at www.crescendobio.com.

Hirata S, Haney DJ, Cavet G, Bolce R, Li W, Defranoux N, Chernoff D, Yamaoka K, Saito K, Tanaka Y. A Multi-Biomarker Disease Activity (Vectra DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patient with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab. Oral Presentation 2664. ACR 2012 Annual Scientific Meeting, Washington DC.

Haney DJ, Cavet G, Durez P, Alten R, Burmester GR, Tak PP, Catrina AI, Gaillez C, Bars ML, Connolly S, Townsend R. Correlation of a Multi-Biomarker Disease Activity Response Assessment to Disease Activity Score 28 (C-Reactive Protein) Response Assessment and OMERACT RAMRIS Scores in a Placebo-Controlled Rheumatoid Arthritis Clinical Trial with Abatacept (ASSET). Poster 2159. ACR 2012 Annual Scientific Meeting, Washington DC.

Biljsma JWJ, Verhoef-Jurgens M, Bakker M, Jacobs JWG, Lafeber FPJ, Welsing PMJ, Cavet G, Chernoff D, Li W, Sasso EH, Haney DJ. Response to Methotrexate Plus Prednisone in CAMERA II Using a Multi-Biomarker Disease Activity (Vectra™ DA) Test and DAS28ESR. Poster 2125. ACR 2012 Annual Scientific Meeting, Washington DC.

Tanaka Y, Hanami K, Tasaka H, Fukuyo S, Haney DJ, Bolce R, Debranoux N, Cavet G, Chernoff D, Yamaoka K, Saito K, Hirata S. A Multi-Biomarker Disease Activity Score (Vectra™ DA algorithm score) Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab. Poster 2121. ACR 2012 Annual Scientific Meeting, Washington DC.

Yamaoka K, Kubo S, Sonomoto K, Hirata S, Cavet G, Bolce R, Rowe M, Chernoff D, Defranoux N, Saito K, Tanaka Y. Correlation of a Multi-Biomarker Disease Activity (Vectra ™ DA) Score with Clinical Disease Activity And Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib. Poster 2162. ACR 2012 Annual Scientific Meeting, Washington DC.

Hensvold AH, Saevarsdottir S, Li W, Lundberg K, Malmstrom V, Cavet G, Defranoux N, Klareskog L, Catrina AI. Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate. Poster 2130. ACR 2012 Annual Scientific Meeting, Washington DC.

Lamberth S, Cherkas Y, Brodmerkel C, Currran M. Utility of Vectra™ DA on Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response: Results of a Pilot Study From a Phase 3 Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Poster 2165. ACR 2012 Annual Scientific Meeting, Washington DC.

van der Helm-van Mil AHM, Knevel R, Qureshi F, Manning WC, Cavet G, Huizinga TWJ, Haney DJ. Evaluation of Definitions of Rheumatoid Arthritis Remission by Assessing Radiographic Progression in the Leiden Early Arthritis Cohort. Poster SAT0082. EULAR Congress 2012.

Hirata S, Dirven L, Cavet G, Shen Y, Centola M, Lerns WF, Tanaka Y, Huizinga TWJ, Allaart CF. A Multi-Biomarker Disease Activity Score (the Vectra™ DA algorithm score) Reflects Clinical Remission for Rheumatoid Arthritis (RA) in the BeSt Study. Poster FRI0132. EULAR Congress 2012.

Hirata S, Haney DJ, Cavet G, Li W, Sawamukai N, Yamaoka K, Saito K, Tanaka Y. A Multi-Biomarker Disease Activity Score (Vectra™ DA algorithm score) Reflects Clinical Disease Activity and Tracks Response in a Japanese Rheumatoid Arthritis Population Treated with Anti-TNF Therapy. Poster FRI0174. EULAR Congress 2012.

Yamaoka K, Kubo S, Sonomoto K, Hirata S, Voinov A, Rowe M, Cavet G, Saito K, Tanaka Y. A Multi-Biomarker Disease Activity Score (MBDA) Score Measures Rheumatoid Arthritis Disease Activity in Patients Treated with the JAK Inhibitor Tofacitinib. Poster THU0145. EULAR Congress 2012.

Allaart CF, Dirven L, Hirata S, Kerstens PJSM, Dijkmans BAC, Chernoff D, Cavet G, Centola M, Hesterberg LK, Tanaka Y. Huizinga TWJ, and Shen Y. A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study. Oral Presentation 1613. ACR 2011 Annual Scientific Meeting, Chicago, IL.

van der Helm-van Mil AHM, Knevel R, Qureshi F, Manning WC, Cavet G, Huizinga TWJ and Haney DJ. Evaluation of Definitions of Rheumatoid Arthritis Remission by Assessing Radiographic Progression in the Leiden Early Arthritis Cohort. Poster 323. ACR 2011 Annual Scientific Meeting, Chicago, IL.

Ma MH, Ramanujan S, Cavet G, Haney DJ, Zhao X, Eastman PS, Kingsley GH, Scott DL and Cope AP. Investigation of a Multi-Biomarker Disease Activity (Vectra DA) Signature and Algorithm Score in Rheumatoid Arthritis Patients with Low Disease Activity: The REMIRA Study. Poster 361. ACR 2011 Annual Scientific Meeting, Chicago, IL.

Hirata S, Dirven L, Cavet G, Shen Y, Centola M, Lems WL, Huizinga TWJ, Allaart CF, and Tanaka Y. A Novel Multi-Biomarker Disease Activity Score (Vectra™DA algorithm score) Reflects Clinical Disease Activity Score and Health Assessment Questionnaire for Rheumatoid Arthritis in the BeSt Study. Poster 351. ACR 2011 Annual Scientific Meeting, Chicago, IL.

Hirata S, Haney DJ, Cavet G, Hesterberg LK, Sawamukai N, Yamaoka K, Saito K, and Tanaka Y. A Multi-Biomarker Disease Activity Score (Vectra™DA algorithm score) Reflects Clinical Disease Activity and Tracks Response in a Japanese Rheumatoid Arthritis Population Treated with Anti-TNF Therapy. Poster 2244. ACR 2011 Annual Scientific Meeting, Chicago, IL.

Weinblatt ME, Shadick NA, Manning W, Coblyn JS, Centola M, Chernoff D, Cavet G, Haney DJ. Use of a Multi-Biomarker Score for Rheumatoid Arthritis Disease Activity (Vectra™ DA) to Assess Response to Therapy. (Poster Session I: May 26, 2011, 11:45 BST). EULAR Congress 2011.

Allaart CF, Dirven L, Hirata S, Kerstens PJ, Dijkmans BA, Chernoff D, Cavet G, Centola M, Hesterberg LK, Tanaka Y, Huizinga TW, Shen Y. A Multi-Biomarker Algorithm for RA Disease Activity (Vectra™ DA) Predicts Radiographic Progression in the BeSt Study. (Poster Session I: May 26, 201, 11:45 BST). EULAR Congress 2011.

Shadick NA, Chernoff D, Hamburger M, Curtis JR, Cavet G, Ford K, Swan K, Haney DJ. Robustness of a Novel Multi-Biomarker Score for RA Disease Activity (Vectra™ DA) Across a Spectrum of Co-Morbidities and Smoking Status. (Poster Session II: May 27, 2011, 11:45 BST). EULAR Congress 2011.

Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, Tanaka Y, Huizinga TW, Allaart CF. A Multi-Biomarker Based Disease Activity (MBDA) Score System Compared to a Conventional Disease Activity Score (DAS) System in the BeSt Rheumatoid Arthritis (RA) Study. (Poster Session III: May 28, 2011, 10:15 BST). EULAR Congress 2011.

Ma MH, Ramanujan S, Haney DJ, Cavet G, Kingsley GH, Scott DL, Cope AP. Biomarker Signatures in Rheumatoid Arthritis Patients with Low Disease Activity: The REMIRA Study. (Poster Session III: May 28, 2011, 10:15 BST). EULAR Congress 2011.

Curtis JR, Haney D, van der Helm A HM, Shen Y, Knevel R, Cavet G, Dirven L, Allaart CF, Huizinga T WJ, Centola M, Hesterberg LK, Chernoff D, Carulli J,Shadick NA, Weinblatt ME, Hamburger MI, Fleischmann RM, Keystone EC. Validation of a Multi-Biomarker Test for Rheumatoid Arthritis (RA) Disease Activity (Vectra™ DA) in a Multi-Cohort Study. Presentation 1782. ACR 2010 Annual Scientific Meeting.

Bakker MF, Shen Y, Bijlsma J WJ, Jacobs J WG, Lafeber F PJG, Cavet G, Centola M, Haney D, Hesterberg LK, Chernoff D, Carulli J, Shadick NA, Weinblatt ME, Hamburger MI, Fleischmann RM, Curtis JR, Keystone EC. Development of a Multi-Biomarker Test for Rheumatoid Arthritis (RA) Disease Activity (Vectra™ DA). Presentation 1753. ACR 2010 Annual Scientific Meeting.

Cavet G, Centola M, Shen Y, Haney D, Smith D, Hesterberg L, Chernoff D, Carulli J, Shadick NA, Weinblatt ME, Hamburger M, Fleischmann R, Keystone EC, Curtis JR and The InFoRM and BRASS Study Groups. Development of a Multi-Biomarker Test for Rheumatoid Arthritis (RA) Disease Activity. Oral Presentation # EULAR2010-SCIE-3851. EULAR Congress 2010. Ann Rheum Dis. 2010; 69 ( Suppl 3):148.

Bakker MF, Bijlsma JWJ, Jacobs JWG, Haney D, Shen Y, Hesterberg LK, Smith D, Centola M, Lafeber FPJG, Cavet G. Performance of Serum Biomarkers and Multivariate Biomarker-Based Test to Measure Disease Activity in Early Rheumatoid Arthritis Treated According to the CAMERA Protocol. Poster # FRI0106. EULAR Congress 2010.

Fleischmann R, Curtis JR, Hamburger M, Blumstein H, Swan K, Cavet G, Chernoff D on behalf of the InFoRM Study Group. RA Population Characteristics in InFoRM: a Longitudinal Observational Study. Poster # SAT0518. EULAR Congress 2010.

Ramanujan S, Centola M, Cavet G, McInnes I. Multi-Protein Biomarker Panel Integrates Critical Pathophysiologic Mechanisms in Measurement of RA Disease Activity. Poster # FRI0034. EULAR Congress 2010.

Shen Y, Knowlton N, Turner M, Sutton C, Smith D, Chernoff D, Hesterberg LK, Carulli J, Shadick NA, Weinblatt ME, Cavet G, Centola M. Stepwise Discovery of Disease Activity Biomarkers in Rheumatoid Arthritis. Poster # THU0066. EULAR Congress 2010.

Shen Y, Knowlton N, Turner M, Sutton C, Smith D, Chernoff D, Hesterberg L, Roubenoff R, Shadick NA, Weinblatt M, Cavet G, Centola M. Stepwise development of a multi-protein biomarker index of RA disease activity.Presentation 345. ACR 2009 Annual Scientific Meeting.

Turner M, Knowlton N, Frank MB, et al. Development of a multivariate disease activity test in rheumatoid arthritis. Presentation 1955. ACR 2008 Annual Scientific Meeting.


Learn more about Using Vectra DA in conjunction with Clinical Assessment

Learn more about the biomarkers in Vectra DA by clicking here.